Trial Profile
A Phase IIa Randomized, Placebo-Controlled Clinical Trial to Study the Safety and Efficacy of MK-0822 in Patients withOsteoarthritis
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Odanacatib (Primary)
- Indications Osteoarthritis
- Focus Therapeutic Use
- Sponsors Merck & Co; Merck Sharp & Dohme
- 18 Nov 2019 This trial has been completed in United Kingdom, according to the European Clinical Trials Database record
- 06 Apr 2007 Status changed from suspended to discontinued, according to ClinicalTrials.gov.
- 01 Apr 2007 Status changed from recruiting to suspended, according to ClinicalTrials.gov.